Zacks: Analysts Expect CONMED Co. (NASDAQ:CNMD) Will Announce Quarterly Sales of $274.75 Million

Equities analysts expect that CONMED Co. (NASDAQ:CNMDGet Rating) will report $274.75 million in sales for the current quarter, Zacks reports. Four analysts have provided estimates for CONMED’s earnings, with estimates ranging from $270.53 million to $278.10 million. CONMED reported sales of $255.16 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 7.7%. The firm is expected to report its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that CONMED will report full year sales of $1.12 billion for the current year, with estimates ranging from $1.11 billion to $1.13 billion. For the next fiscal year, analysts expect that the company will post sales of $1.23 billion, with estimates ranging from $1.19 billion to $1.27 billion. Zacks’ sales averages are a mean average based on a survey of research firms that cover CONMED.

Separately, StockNews.com started coverage on shares of CONMED in a research note on Thursday, March 31st. They issued a “hold” rating on the stock.

Shares of NASDAQ:CNMD traded up $0.74 during trading on Friday, hitting $112.45. The company’s stock had a trading volume of 204,653 shares, compared to its average volume of 279,235. CONMED has a 12 month low of $107.08 and a 12 month high of $159.11. The company has a quick ratio of 1.25, a current ratio of 2.60 and a debt-to-equity ratio of 0.89. The stock has a market capitalization of $3.32 billion, a PE ratio of 53.55, a price-to-earnings-growth ratio of 2.57 and a beta of 1.51.

About CONMED (Get Rating)

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. It offers orthopedic surgery products, including TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and PopLok Knotless Suture Anchors, which provide unique clinical solutions to orthopedic surgeons for the repair of soft tissue injuries, as well as supporting products that enable surgeons to perform minimally invasive sports medicine surgeries.

Read More

Get a free copy of the Zacks research report on CONMED (CNMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for CONMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED and related companies with MarketBeat.com's FREE daily email newsletter.